Eli Lilly CEO on why food companies haven’t seen a big impact on sales

CNBC’s Angelica Peebles and Eli Lilly chairman and CEO David Ricks join ‘Squawk on the Street’ to discuss results of the company’s 3-year obesity study, which showed its highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo.